PMID- 29933533
OWN - NLM
STAT- MEDLINE
DCOM- 20180731
LR  - 20221207
IS  - 0255-2922 (Print)
IS  - 0255-2922 (Linking)
VI  - 36
IP  - 5
DP  - 2016 Oct
TI  - Efficacy and safety of Sancai powder in patients with type 2 diabetes mellitus: a 
      randomized controlled trial.
PG  - 640-8
AB  - OBJECTIVE: To assess the efficacy and safety of Sancai powder in patients with 
      type 2 diabetes mellitus (T2DM) inadequately controlled with single oral 
      metformin in a randomized controlled trial (RCT). METHODS: A total of 132 
      patients with T2DM were enrolled in the study, who only took metformin (500-1000 
      mg/day) for at least three months and with inadequate glycemic control (7.0% </= 
      hemoglobin A1c </= 9.0% ) in the past three months. The patients stopped taking 
      metformin with lifestyle interventions for three weeks, and 105 patients 
      qualified for the program. They were randomly divided into the Sancai powder 
      group and the metformin group (1500 mg/day). The follow-up period was for 12 
      weeks. Comparisons of several variables were analyzed. RESULTS: No significant 
      differences were found between the two groups in hemoglobin A1c (HbA1c), fasting 
      plasma glucose (FPG) and 2 h post-meal glucose (2hPG), although they had 
      decreased significantly (P < 0.01). Homeostasis model assessment of beta cell 
      function index was significantly improved in Sancai powder group (P < 0.01), and 
      there were significant differences in the changes of homeostasis model assessment 
      of insulin resistance and insulin sensitivity index in the two groups (P < 0.05). 
      Sancai powder significantly reduced triglyceride level (P < 0.05), although there 
      was no significant difference in the body weight and body mass index in the two 
      groups. CONCLUSION: In this 12-week study, Sancai powder could significantly 
      reduce hemoglobin A1c, FPG and 2hPG levels, improved beta-cell function and 
      insulin resistance of the T2DM inadequately controlled with metformin.
FAU - Guo, Qiang
AU  - Guo Q
FAU - Zhang, Hengyao
AU  - Zhang H
FAU - Li, Mindian
AU  - Li M
FAU - Zhao, Ziyi
AU  - Zhao Z
FAU - Luo, Yunlin
AU  - Luo Y
FAU - Luo, Yulei
AU  - Luo Y
FAU - Cao, Wenzhai
AU  - Cao W
FAU - Zhao, Huan
AU  - Zhao H
FAU - Zhu, Ranran
AU  - Zhu R
FAU - Lei, Xingxing
AU  - Lei X
FAU - Chen, Huizhen
AU  - Chen H
FAU - Gan, Huakui
AU  - Gan H
FAU - Zuo, Zhihuang
AU  - Zuo Z
FAU - Chen, Qi
AU  - Chen Q
FAU - Shi, Cuimei
AU  - Shi C
FAU - Zhang, Xinli
AU  - Zhang X
FAU - Guo, Jian
AU  - Guo J
FAU - Zhong, Sen
AU  - Zhong S
FAU - Chen, Qiu
AU  - Chen Q
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - J Tradit Chin Med
JT  - Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan
JID - 8211546
RN  - 0 (Blood Glucose)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Blood Glucose/metabolism
MH  - Body Weight/drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism/physiopathology
MH  - Drugs, Chinese Herbal/*administration & dosage/adverse effects
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Male
MH  - Metformin/administration & dosage
MH  - Middle Aged
MH  - Young Adult
EDAT- 2016/10/01 00:00
MHDA- 2016/10/01 00:01
CRDT- 2018/06/23 06:00
PHST- 2018/06/23 06:00 [entrez]
PHST- 2016/10/01 00:00 [pubmed]
PHST- 2016/10/01 00:01 [medline]
AID - 10.1016/s0254-6272(16)30084-x [doi]
PST - ppublish
SO  - J Tradit Chin Med. 2016 Oct;36(5):640-8. doi: 10.1016/s0254-6272(16)30084-x.